Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Investors who lost money on Travere Therapeutics, Inc. should contact Levi & Korsinsky about an ongoing investigation - TVTX
NEW YORK, NY / ACCESSWIRE / October 1, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Travere Therapeutics, Inc. ("Travere Therapeutics, Inc.") (NASDAQ:TVTX) concerning possible violations of federal securities laws. Travere issued a press release on September 26, 2024, "announc[ing] a voluntary pause of enrollment in the Phase 3 HARMONY Study evaluating pegtibatinase for the treatment of classical homocystinuria (HCU).
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / October 1, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Travere Therapeutics, Inc. ("Travere" or "the Company") (NASDAQ:TVTX). Investors who purchased Travere securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/TVTX.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTX
NEW YORK, NY / ACCESSWIRE / September 30, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Travere Therapeutics, Inc. ("Travere" or the "Company") (NASDAQ:TVTX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
Travere Therapeutics specializes in rare kidney and metabolic disease treatments with key drugs Filspari and Thiola. Filspari, a key asset for IgA Nephropathy, has received full FDA approval, and its market potential is significant if indications expand. Travere faces risks from supply constraints and paused Pegtibatinase trial, but these are seen as temporary headwinds rather than long-term issues.
Travere (TVTX) Soars 5.9%: Is Further Upside Left in the Stock?
Travere (TVTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Travere Gains 11% on Securing Full FDA Nod for Kidney Disease Drug
The approval expands the label of TVTX's Filspari in IgAN indication. However, the label also comes with a boxed warning for liver problems and congenital disabilities.
Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease
Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.
Travere Therapeutics: Judgement Day Is Nigh For Sparsentan
Travere Therapeutics' stock has been volatile due to Filspari's failed Phase 3 trials, but a full FDA approval is possible next week that could boost its share price. Despite setbacks, Filspari's unique dual-pathway mechanism and promising clinical data make FDA denial unlikely, supporting a bullish outlook. Travere's financial health is precarious, with significant losses and a potential need for additional funding, but a buyout could be a favorable outcome.
Travere Therapeutics, Inc. (TVTX) Q2 2024 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Nivi Nehra - Vice President of Corporate Communications and Investor Relations Eric Dube - President and CEO Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - CFO Bill Rote - Senior Vice President of Research & Development Conference Call Participants Tyler Van Buren - TD Cowen Anupam Rama - JPMorgan Joseph Schwartz - Leerink Partners Carter Gould - Barclays Pavan Patel - Bank of America Maurice Raycroft - Jefferies Alex Thompson - Stifel Vamil Divan - Guggenheim Securities Thomas Yip - H.C. Wainwright Operator Good day, and welcome to the Travere Therapeutics' Second Quarter 2024 Financial Results and Corporate Update Conference Call.
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.87. This compares to loss of $1.13 per share a year ago.
Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
